Leerink Partnrs Brokers Raise Earnings Estimates for Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company (NYSE:LLYFree Report) – Equities research analysts at Leerink Partnrs lifted their FY2026 earnings per share estimates for shares of Eli Lilly and Company in a note issued to investors on Thursday, February 8th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings of $24.53 per share for the year, up from their previous estimate of $22.31. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $12.52 per share. Leerink Partnrs also issued estimates for Eli Lilly and Company’s FY2027 earnings at $31.95 EPS and FY2028 earnings at $38.60 EPS.

Eli Lilly and Company (NYSE:LLYGet Free Report) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 50.78% and a net margin of 15.36%. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same period last year, the business posted $2.09 earnings per share. The firm’s revenue was up 28.1% compared to the same quarter last year.

Other research analysts have also issued reports about the company. BMO Capital Markets increased their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, November 3rd. Deutsche Bank Aktiengesellschaft started coverage on Eli Lilly and Company in a report on Thursday, November 9th. They set a “hold” rating and a $535.00 target price on the stock. Truist Financial raised their target price on Eli Lilly and Company from $650.00 to $850.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. Finally, Wells Fargo & Company raised their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $621.81.

Read Our Latest Stock Report on Eli Lilly and Company

Eli Lilly and Company Stock Down 0.3 %

Shares of LLY stock opened at $737.68 on Monday. The stock’s 50-day simple moving average is $623.06 and its 200-day simple moving average is $583.91. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.82 and a current ratio of 1.05. The firm has a market capitalization of $700.29 billion, a PE ratio of 127.19, a P/E/G ratio of 2.08 and a beta of 0.32. Eli Lilly and Company has a fifty-two week low of $309.20 and a fifty-two week high of $745.70.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Thursday, February 15th will be issued a $1.30 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.13. This represents a $5.20 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and Company’s payout ratio is presently 77.93%.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders sold 195,055 shares of company stock valued at $125,254,657. Insiders own 0.13% of the company’s stock.

Institutional Trading of Eli Lilly and Company

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in shares of Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after acquiring an additional 659,838 shares during the period. State Street Corp grew its holdings in shares of Eli Lilly and Company by 1.9% in the 2nd quarter. State Street Corp now owns 33,878,417 shares of the company’s stock worth $15,888,300,000 after acquiring an additional 642,274 shares during the period. Geode Capital Management LLC grew its holdings in shares of Eli Lilly and Company by 2.3% in the 2nd quarter. Geode Capital Management LLC now owns 15,205,501 shares of the company’s stock worth $7,111,568,000 after acquiring an additional 338,077 shares during the period. Morgan Stanley grew its holdings in shares of Eli Lilly and Company by 0.7% in the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after acquiring an additional 83,915 shares during the period. Finally, Norges Bank acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $5,992,890,000. 81.38% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading

Earnings History and Estimates for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.